All three major US stock indexes were up in late-morning trading Friday and are poised to secure a winning week.

In company news, Trade Desk (TTD) reported fiscal Q2 non-GAAP net income late Thursday of $0.41 per diluted share, up from $0.39 a year earlier and in-line with the FactSet consensus analyst estimate. Fiscal Q2 revenue was $694 million, up from $585 million a year ago and above the FactSet consensus of $685.5 million. For fiscal Q3, the company expects revenue of at least $717 million, above the FactSet consensus of $716.1 million. The company also said it has named Alex Kayyal as its chief financial officer, effective Aug. 21. Chief Executive Jeff Green said on Trade Desk's earnings call that its results were impacted by ongoing tariff uncertainty on its key clients -- large global advertisers. Trade Desk shares were down 39.3% around midday.

The UK's Competition and Markets Authority said Friday that it has approved Boeing's (BA) planned acquisition of Spirit AeroSystems (SPR). Boeing shares were up 1.1%, while those of Spirit AeroSystems were up 0.7%.

Tesla (TSLA) is disbanding its Dojo supercomputer team, Bloomberg reported Friday, citing people familiar with the matter. The team has lost nearly 20 workers recently to DensityAI, the people told Bloomberg. Remaining Dojo workers are being reallocated to other data center projects, according to the report. Separately, Tesla Robotaxi is now listed as a transportation network company licensee with the Texas Department of Licensing and Regulation. Tesla shares were up 3.4%.

GSK (GSK) said Friday it will receive $370 million in its mRNA patent settlement deal between CureVac (CVAC) and BioNTech (BNTX). The settlement is related to an existing licensing agreement with CureVac, and GSK said it will also be entitled to a 1% royalty on BioNTech and Pfizer's (PFE) US sales of influenza, COVID-19 and related combination mRNA vaccine products from the start of 2025. GSK will receive an extra $130 million in cash and a 1% royalty if BioNTech completes its acquisition of CureVac, which will also settle the companies' mRNA patent litigation outside of the US. The royalty is applicable to BioNTech and Pfizer's future sales outside of the US, the company said. GSK shares were up 0.7%, while those of CureVac and BioNTech were down 0.3% and up 0.8%, respectively. Pfizer shares were up 0.7%.

Under Armour (UA) reported fiscal Q1 adjusted diluted EPS Friday of $0.02, up from $0.01 a year earlier and in-line with the FactSet consensus. Fiscal Q1 net revenue was $1.13 billion, down from $1.18 billion a year ago and in-line with the FactSet consensus. For fiscal Q2, the company said it expects adjusted diluted EPS of $0.01 to $0.02. Analysts polled by FactSet expect $0.26. Fiscal Q2 revenue is expected to fall by 6% to 7%. Under Armour shares were down 20.1%.

Goodyear Tire & Rubber (GT) reported a Q2 adjusted loss late Thursday of $0.17 per diluted share, swinging from positive $0.17 a year earlier and below the FactSet consensus estimate of $0.02. Second-quarter revenue was $4.47 billion, down from $4.57 billion a year ago and in-line with the FactSet consensus estimate. Goodyear shares were down 18.5%.

Price: 53.86, Change: -34.48, Percent Change: -39.03